Evident buys Rome microscopy maker CrestOptics to expand 3D imaging
What's the deal? Evident ScientificDealroom has a profile for this one. Try Dealroom → has completed its acquisition of CrestOpticsDealroom has a profile for this one. Try Dealroom →, a Rome-based developer and manufacturer of optical imaging systems for spinning-disk confocal and super-resolution microscopy. Terms were not disclosed. The deal expands Evident's life-science imaging portfolio and its capabilities in fast, high-throughput 3D imaging for research, pharma, and biotech.
What each company does: Founded in 2011, CrestOptics builds confocal spinning-disk and structured illumination microscopy modules that integrate into platforms from leading microscope makers. Its products include the X-Light spinning-disk systems, the compact CICERO confocal solution, and DeepSIM, a lattice-SIM super-resolution module. Evident, which continues the OlympusDealroom has a profile for this one. Try Dealroom → microscopy legacy, sells imaging tools spanning brightfield, fluorescence, and 4D analysis.
Why now? The two firms have partnered for several years, with CrestOptics' spinning-disk technology already built into Evident microscope configurations. The acquisition formalises and extends that relationship.
What's the endgame? "Researchers are asking increasingly demanding questions of ever more complex biological models, and that requires faster, gentler, higher-resolution imaging," said Wes Pringle, chief executive officer of Evident (translated from German). CrestOptics will keep operating from its Rome headquarters and its R&D and production site, maintaining its partner and distribution relationships.
What changes for customers? CrestOptics CEO Renato Giacobbo Scavo said joining Evident gives the company "global reach, manufacturing expertise, and applications expertise" to speed its innovation and reach more labs. He thanked former investors Apposite CapitalDealroom has a profile for this one. Try Dealroom → and Primo CapitalDealroom has a profile for this one. Try Dealroom →. The company plans to stay a technology supplier to the wider microscopy industry.
The signal: The deal is another step in consolidation across scientific imaging, as larger players absorb specialist developers to round out portfolios for research, pharma, and biotech customers chasing faster, higher-resolution tools.
Read more: prnewswire.com
Image credit: Crest Optics
